other material
confidence high
sentiment positive
materiality 0.40
Oncolytics says new pelareorep method-of-use patents extend IP protection into late 2040s
ONCOLYTICS BIOTECH INC
- New method-of-use patent covering pelareorep as a cancer immunotherapy issued in several countries; corresponding U.S. patent expected in the near term.
- Existing manufacturing patent protection runs through 2044; company targets extension into the late 2040s via new patents.
- Three patent application families pending, including multiple method-of-use filings covering pelareorep with immunotherapies and targeted therapies.
- Company expects to convert one pending application to a USPTO Track One prioritized examination this quarter, targeting final disposition in ~12 months.
- Working with an academic partner on 'next generation' modified pelareorep; a new composition of matter patent could add up to 20 years from filing, CEO Jared Kelly said.